Related Experiment Video
Updated: Oct 16, 2025

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
Published on: May 26, 2015
Folic Acid Attenuates Contrast-Induced Nephropathy in Patients With Hyperhomocysteinemia Undergoing Coronary
Long Peng1, Xing Shui1, Fang Tan2,3
1Department of Cardiovascular Medicine, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Insights
Folic acid supplementation significantly reduced the incidence of contrast-induced nephropathy (CIN) in patients with hyperhomocysteinemia undergoing coronary catheterization. This intervention offers a protective strategy against kidney damage following contrast procedures.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Hyperhomocysteinemia is a recognized risk factor for contrast-induced nephropathy (CIN).
- Previous studies in rats suggested folic acid could mitigate nephropathies, but human data were lacking.
- This study investigated the efficacy of folic acid in preventing CIN in human patients with elevated homocysteine levels undergoing coronary procedures.
Observation:
- A prospective, double-blind, randomized controlled trial was conducted with 412 patients with plasma homocysteine ≥15 μM.
- Patients received either 5 mg of folic acid or a placebo perioperatively.
- CIN was defined by a significant increase in serum creatinine within 48-72 hours post-procedure.
Findings:
- The incidence of CIN was significantly lower in the folic acid treatment group (8% at 48h, 9% at 72h) compared to the placebo group (16% at 48h, 17% at 72h).
- Logistic regression confirmed folic acid administration as a protective factor against CIN (P=0.019).
- No serious adverse events were associated with folic acid, and no deaths or need for hemodialysis occurred in either group.
Implications:
- Perioperative folic acid administration appears to be a safe and effective strategy to attenuate CIN in patients with hyperhomocysteinemia.
- This finding suggests a potential clinical application of folic acid for kidney protection in individuals undergoing contrast-enhanced cardiovascular procedures.
- Further research may explore optimal dosing and long-term outcomes of folic acid in this patient population.
Abstract:
Background: Hyperhomocysteinemia is a risk factor for contrast-induced nephropathy. Folic acid can attenuate such nephropathies in rats. The protective effect of folic acid against contrast-induced nephropathy has not been studied in humans. We aimed to investigate the effect of folic acid on the incidence of contrast-induced nephropathy (CIN) after coronary catheterization in patients with hyperhomocysteinemia. Methods: This was a single-center, prospective, double-blind, randomized controlled trial (ClinicalTrials.gov, NCT02444013). In total, 412 patients (mean age: 65 ± 12 years, 268 male) with plasma homocysteine ≥15 μM, who underwent coronary arteriography (CAG) or percutaneous coronary intervention (PCI) from May 2015 to August 2018, were enrolled. Patients were randomly assigned to two groups: a treatment group (n = 203), taking 5 mg of folic acid (orally, three times/day) immediately after enrollment and for 72 h after operation, and a control group (n = 209), taking placebo. Contrast-induced nephropathy was defined as an increase in serum creatinine of >25% or 44 μM within 48 or 72 h after contrast medium administration. Results: In total, 50 (12%) patients developed CIN after 48 h after catheterization, including 16 (8%) in the treatment group and 34 (16%) in the control group (P = 0.009). Meanwhile, 53 (13%) patients developed CIN after 72 h of CAG/PCI, including 18 (9%) in the treatment group and 35 (17%) in the control group (P = 0.017). The incidence of contrast-induced nephropathy in the treatment group was lower than that in the control group (P = 0.017). Logistic regression analysis confirmed that administration of folic acid was a protective factor against contrast-induced nephropathy (RD = 0.0788, 95%CI: 0.0105-0.1469, P = 0.019). We found no serious adverse events associated with folic acid. No death or hemodialysis occurred in either group. Conclusions: Perioperative administration of folic acid attenuates the incidence of contrast-induced nephropathy after coronary catheterization in patients with hyperhomocysteinemia. Clinical Trial Registration: ClinicalTrials.gov, identifier [NCT02444013].
More Related Videos
Related Concept Videos
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Imaging Studies VII: Vascular Imaging
Acute Coronary Syndrome III: Diagnostic Studies
Imaging Studies for Cardiovascular System V: CT

